Ibrutinib provides long term survival benefits to patients with chronic lymphocytic leukemia (CLL) regardless of cytogenetic risk factors, according to 4-year follow-up data being presented the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.1

For the randomized phase 3 RESONATE trial (ClinicalTrials.gov Identifier: NCT01578707), researchers evaluated whether ibrutinib — a Bruton’s kinase inhibitor — would improve outcomes over ofatumumab among patients with CLL.

Of 391 enrolled patients, 195 received ibrutinib and 196 received ofatumumab. At a median 9-month interim analysis, crossover from ofatumumab to ibrutinib was recommended for all patients due to efficacy, though overall survival data for crossover patients were censored.

Median follow-up in the ibrutinib arm was 44 months. The median progression-free survival (PFS) was not reached in the ibrutinib arm vs 8 months in the ofatumumab arm; 3-year PFS was 59% vs 3%, respectively.

Related Articles

The 3-year overall survival rate in the ibrutinib group was 74%. The overall response rate with ibrutinib was 91% with complete responses increasing over time.

Grade 3 or worse adverse events decreased in frequency after 1 year. By 4-year follow up, 39% of patients discontinued ibrutinib for disease progression or adverse events.

Ninety of the enrolled patients are still receiving ibrutinib.


  1. Byrd JC, Hillmen P, O’Brien SM, et al. Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study. J Clin Oncol. 2017;35(suppl; abstr 7510).

This article originally appeared on Cancer Therapy Advisor